Despite numerous advances in the management of heart failure, hospital admission and readmission rates remain high with patients requiring complex, coordinated care. The goal of this activity is to help cardiologists and other healthcare professionals improve clinical outcomes in their patients with heart failure. The roundtable discussion will focus on the identification and classification of heart failure, the integration of current evidence-based recommendations, and the optimization of pharmacologic therapies for patients with heart failure in order to reduce admission rates and improve patient health outcomes. 

Learning Objectives

  • Assess and classify patients with HF based on an understanding of underlying pathophysiology, disease stage, comorbidities, and other clinical factors so as to better reduce hospital admissions and readmissions, morbidity, mortality
  • Individualize treatment of patients with HF based on their clinical presentation and in alignment with the latest evidence-based guideline recommendations for management
  • Appropriately select therapeutic options based on a sound understanding of current studies of angiotensin-converting enzyme (ACE) inhibitors, ß-blockers, angiotensin receptor blockers (ARBs), vasodilators, and new agents such as If channel inhibitor and angiotensin receptorneprilysin inhibitor 

Faculty Disclosures

Akshay S. Desai, MD, MPH

Advisory Board for AstraZeneca; Cheetah Medical Inc.; DalCor Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and St. Jude Medical, Inc. Contracted Research for Novartis Pharmaceuticals Corporation. 

Marc A. Pfeffer, MD, PhD

Consultant for AstraZeneca; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; DalCor Pharmaceuticals; Genzyme; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Relypsa; Sanofi US; and Teva Pharmaceuticals. Contracted Research for Novartis. Ownership Interest (e.g. stock, patent holder) in DalCor Pharmaceuticals. 

Scott D. Solomon, MD

Advisory Boards for Alnylam Pharmaceuticals, Inc.; Amgen Inc.; AstraZeneca; Bayer; Bristol-Myers Squibb Company; Corvia Medical, Inc; Gilead Sciences Medical Affairs; GlaxoSmithKline; Ironwood Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Takeda Pharmaceutical Company; and Theracos, Inc. Contracted Research for Alnylam Pharmaceuticals, Inc.; Amgen Inc.; AstraZeneca; Bellerophon Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Eiger BioPharmaceuticals; Gilead Sciences Medical Affairs; GlaxoSmithKline; Ionis Pharmaceuticals, Inc.; LoneStar Heart, Inc.; Mesoblast Ltd; MyoKardia; National Institutes of Health; Novartis Pharmaceuticals Corporation; and Sanofi Pasteur SA. 


Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME/CE Information


AMA PRA Category 1 Credits

Accreditation Statement

pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

pmiCME designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Accreditation Statement

pmiCME is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider number 040308. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Designation Statement

This program has been approved for 1.50 contact hours of continuing education, including 0.60 hour of pharmacology. 

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 3 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen.

Commercial Supporter

Novartis Pharmaceuticals Corporation

Education Partner


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.

Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.